In this report, the Asia-Pacific RNAi for Therapeutic market is valued at USD XX million in 2019 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2019 and 2025. Geographically, this report split Asia-Pacific into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of RNAi for Therapeutic for these regions, from 2019 to 2025 (forecast), including China Japan South Korea Taiwan India Southeast Asia Australia Asia-Pacific RNAi for Therapeutic market competition by top manufacturers/players, with RNAi for Therapeutic sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including Alnylam Pharmaceuticals Arbutus Biopharma (Tekmira) Arrowhead Research Dicerna Pharmaceuticals Mirna Therapeutics Quark Pharmaceuticals RXi Pharmaceuticals Silence Therapeutics Benitec Biopharma Miragen Therapeutics Sylentis Gradalis Sirnaomics Silenseed Arcturus Therapeutics Ariz Biopharma Celsion Corporation Ascletis Pharmaceuticals On the basis of product, this report displays the sales volum, revenue, product price, market share and growth rate of each type, primarily split into siRNA miRNA shRNA On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including Cancer Cardiovascular HBV Other If you have any special requirements, please let us know and we will offer you the report as you want.
Table of Contents Asia-Pacific RNAi for Therapeutic Market Report 2019 1 RNAi for Therapeutic Overview 1.1 Product Overview and Scope of RNAi for Therapeutic 1.2 Classification of RNAi for Therapeutic by Product Category 1.2.1 Asia-Pacific RNAi for Therapeutic Market Size (Sales) Comparison by Types ( 2014-2024) 1.2.2 Asia-Pacific RNAi for Therapeutic Market Size (Sales) Market Share by Type (Product Category) in 2018 1.2.3 siRNA 1.2.4 miRNA 1.2.5 shRNA 1.3 Asia-Pacific RNAi for Therapeutic Market by Application/End Users 1.3.1 Asia-Pacific RNAi for Therapeutic Sales (Volume) and Market Share Comparison by Applications ( 2014-2024) 1.3.2 Cancer 1.3.3 Cardiovascular 1.3.4 HBV 1.3.5 Other 1.4 Asia-Pacific RNAi for Therapeutic Market by Region 1.4.1 Asia-Pacific RNAi for Therapeutic Market Size (Value) Comparison by Region ( 2014-2024) 1.4.2 China Status and Prospect ( 2014-2024) 1.4.3 Japan Status and Prospect ( 2014-2024) 1.4.4 South Korea Status and Prospect ( 2014-2024) 1.4.5 Taiwan Status and Prospect ( 2014-2024) 1.4.6 India Status and Prospect ( 2014-2024) 1.4.7 Southeast Asia Status and Prospect ( 2014-2024) 1.4.8 Australia Status and Prospect ( 2014-2024) 1.5 Asia-Pacific Market Size (Value and Volume) of RNAi for Therapeutic ( 2014-2024) 1.5.1 Asia-Pacific RNAi for Therapeutic Sales and Growth Rate ( 2014-2024) 1.5.2 Asia-Pacific RNAi for Therapeutic Revenue and Growth Rate ( 2014-2024) 2 Asia-Pacific RNAi for Therapeutic Competition by Players/Suppliers, Region, Type and Application 2.1 Asia-Pacific RNAi for Therapeutic Market Competition by Players/Suppliers 2.1.1 Asia-Pacific RNAi for Therapeutic Sales Volume and Market Share of Key Players/Suppliers ( 2014-2019) 2.1.2 Asia-Pacific RNAi for Therapeutic Revenue and Share by Players/Suppliers ( 2014-2019) 2.2 Asia-Pacific RNAi for Therapeutic (Volume and Value) by Type 2.2.1 Asia-Pacific RNAi for Therapeutic Sales and Market Share by Type ( 2014-2019) 2.2.2 Asia-Pacific RNAi for Therapeutic Revenue and Market Share by Type ( 2014-2019) 2.3 Asia-Pacific RNAi for Therapeutic (Volume) by Application 2.4 Asia-Pacific RNAi for Therapeutic (Volume and Value) by Region 2.4.1 Asia-Pacific RNAi for Therapeutic Sales and Market Share by Region ( 2014-2019) 2.4.2 Asia-Pacific RNAi for Therapeutic Revenue and Market Share by Region ( 2014-2019) 3 China RNAi for Therapeutic (Volume, Value and Sales Price) 3.1 China RNAi for Therapeutic Sales and Value ( 2014-2019) 3.1.1 China RNAi for Therapeutic Sales Volume and Growth Rate ( 2014-2019) 3.1.2 China RNAi for Therapeutic Revenue and Growth Rate ( 2014-2019) 3.1.3 China RNAi for Therapeutic Sales Price Trend ( 2014-2019) 3.2 China RNAi for Therapeutic Sales Volume and Market Share by Type 3.3 China RNAi for Therapeutic Sales Volume and Market Share by Application 4 Japan RNAi for Therapeutic (Volume, Value and Sales Price) 4.1 Japan RNAi for Therapeutic Sales and Value ( 2014-2019) 4.1.1 Japan RNAi for Therapeutic Sales Volume and Growth Rate ( 2014-2019) 4.1.2 Japan RNAi for Therapeutic Revenue and Growth Rate ( 2014-2019) 4.1.3 Japan RNAi for Therapeutic Sales Price Trend ( 2014-2019) 4.2 Japan RNAi for Therapeutic Sales Volume and Market Share by Type 4.3 Japan RNAi for Therapeutic Sales Volume and Market Share by Application 5 South Korea RNAi for Therapeutic (Volume, Value and Sales Price) 5.1 South Korea RNAi for Therapeutic Sales and Value ( 2014-2019) 5.1.1 South Korea RNAi for Therapeutic Sales Volume and Growth Rate ( 2014-2019) 5.1.2 South Korea RNAi for Therapeutic Revenue and Growth Rate ( 2014-2019) 5.1.3 South Korea RNAi for Therapeutic Sales Price Trend ( 2014-2019) 5.2 South Korea RNAi for Therapeutic Sales Volume and Market Share by Type 5.3 South Korea RNAi for Therapeutic Sales Volume and Market Share by Application 6 Taiwan RNAi for Therapeutic (Volume, Value and Sales Price) 6.1 Taiwan RNAi for Therapeutic Sales and Value ( 2014-2019) 6.1.1 Taiwan RNAi for Therapeutic Sales Volume and Growth Rate ( 2014-2019) 6.1.2 Taiwan RNAi for Therapeutic Revenue and Growth Rate ( 2014-2019) 6.1.3 Taiwan RNAi for Therapeutic Sales Price Trend ( 2014-2019) 6.2 Taiwan RNAi for Therapeutic Sales Volume and Market Share by Type 6.3 Taiwan RNAi for Therapeutic Sales Volume and Market Share by Application 7 India RNAi for Therapeutic (Volume, Value and Sales Price) 7.1 India RNAi for Therapeutic Sales and Value ( 2014-2019) 7.1.1 India RNAi for Therapeutic Sales Volume and Growth Rate ( 2014-2019) 7.1.2 India RNAi for Therapeutic Revenue and Growth Rate ( 2014-2019) 7.1.3 India RNAi for Therapeutic Sales Price Trend ( 2014-2019) 7.2 India RNAi for Therapeutic Sales Volume and Market Share by Type 7.3 India RNAi for Therapeutic Sales Volume and Market Share by Application 8 Southeast Asia RNAi for Therapeutic (Volume, Value and Sales Price) 8.1 Southeast Asia RNAi for Therapeutic Sales and Value ( 2014-2019) 8.1.1 Southeast Asia RNAi for Therapeutic Sales Volume and Growth Rate ( 2014-2019) 8.1.2 Southeast Asia RNAi for Therapeutic Revenue and Growth Rate ( 2014-2019) 8.1.3 Southeast Asia RNAi for Therapeutic Sales Price Trend ( 2014-2019) 8.2 Southeast Asia RNAi for Therapeutic Sales Volume and Market Share by Type 8.3 Southeast Asia RNAi for Therapeutic Sales Volume and Market Share by Application 9 Australia RNAi for Therapeutic (Volume, Value and Sales Price) 9.1 Australia RNAi for Therapeutic Sales and Value ( 2014-2019) 9.1.1 Australia RNAi for Therapeutic Sales Volume and Growth Rate ( 2014-2019) 9.1.2 Australia RNAi for Therapeutic Revenue and Growth Rate ( 2014-2019) 9.1.3 Australia RNAi for Therapeutic Sales Price Trend ( 2014-2019) 9.2 Australia RNAi for Therapeutic Sales Volume and Market Share by Type 9.3 Australia RNAi for Therapeutic Sales Volume and Market Share by Application 10 Asia-Pacific RNAi for Therapeutic Players/Suppliers Profiles and Sales Data 10.1 Alnylam Pharmaceuticals 10.1.1 Company Basic Information, Manufacturing Base and Competitors 10.1.2 RNAi for Therapeutic Product Category, Application and Specification 10.1.2.1 Product A 10.1.2.2 Product B 10.1.3 Alnylam Pharmaceuticals RNAi for Therapeutic Sales, Revenue, Price and Gross Margin ( 2014-2019) 10.1.4 Main Business/Business Overview 10.2 Arbutus Biopharma (Tekmira) 10.2.1 Company Basic Information, Manufacturing Base and Competitors 10.2.2 RNAi for Therapeutic Product Category, Application and Specification 10.2.2.1 Product A 10.2.2.2 Product B 10.2.3 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Sales, Revenue, Price and Gross Margin ( 2014-2019) 10.2.4 Main Business/Business Overview 10.3 Arrowhead Research 10.3.1 Company Basic Information, Manufacturing Base and Competitors 10.3.2 RNAi for Therapeutic Product Category, Application and Specification 10.3.2.1 Product A 10.3.2.2 Product B 10.3.3 Arrowhead Research RNAi for Therapeutic Sales, Revenue, Price and Gross Margin ( 2014-2019) 10.3.4 Main Business/Business Overview 10.4 Dicerna Pharmaceuticals 10.4.1 Company Basic Information, Manufacturing Base and Competitors 10.4.2 RNAi for Therapeutic Product Category, Application and Specification 10.4.2.1 Product A 10.4.2.2 Product B 10.4.3 Dicerna Pharmaceuticals RNAi for Therapeutic Sales, Revenue, Price and Gross Margin ( 2014-2019) 10.4.4 Main Business/Business Overview 10.5 Mirna Therapeutics 10.5.1 Company Basic Information, Manufacturing Base and Competitors 10.5.2 RNAi for Therapeutic Product Category, Application and Specification 10.5.2.1 Product A 10.5.2.2 Product B 10.5.3 Mirna Therapeutics RNAi for Therapeutic Sales, Revenue, Price and Gross Margin ( 2014-2019) 10.5.4 Main Business/Business Overview 10.6 Quark Pharmaceuticals 10.6.1 Company Basic Information, Manufacturing Base and Competitors 10.6.2 RNAi for Therapeutic Product Category, Application and Specification 10.6.2.1 Product A 10.6.2.2 Product B 10.6.3 Quark Pharmaceuticals RNAi for Therapeutic Sales, Revenue, Price and Gross Margin ( 2014-2019) 10.6.4 Main Business/Business Overview 10.7 RXi Pharmaceuticals 10.7.1 Company Basic Information, Manufacturing Base and Competitors 10.7.2 RNAi for Therapeutic Product Category, Application and Specification 10.7.2.1 Product A 10.7.2.2 Product B 10.7.3 RXi Pharmaceuticals RNAi for Therapeutic Sales, Revenue, Price and Gross Margin ( 2014-2019) 10.7.4 Main Business/Business Overview 10.8 Silence Therapeutics 10.8.1 Company Basic Information, Manufacturing Base and Competitors 10.8.2 RNAi for Therapeutic Product Category, Application and Specification 10.8.2.1 Product A 10.8.2.2 Product B 10.8.3 Silence Therapeutics RNAi for Therapeutic Sales, Revenue, Price and Gross Margin ( 2014-2019) 10.8.4 Main Business/Business Overview 10.9 Benitec Biopharma 10.9.1 Company Basic Information, Manufacturing Base and Competitors 10.9.2 RNAi for Therapeutic Product Category, Application and Specification 10.9.2.1 Product A 10.9.2.2 Product B 10.9.3 Benitec Biopharma RNAi for Therapeutic Sales, Revenue, Price and Gross Margin ( 2014-2019) 10.9.4 Main Business/Business Overview 10.10 Miragen Therapeutics 10.10.1 Company Basic Information, Manufacturing Base and Competitors 10.10.2 RNAi for Therapeutic Product Category, Application and Specification 10.10.2.1 Product A 10.10.2.2 Product B 10.10.3 Miragen Therapeutics RNAi for Therapeutic Sales, Revenue, Price and Gross Margin ( 2014-2019) 10.10.4 Main Business/Business Overview 10.11 Sylentis 10.12 Gradalis 10.13 Sirnaomics 10.14 Silenseed 10.15 Arcturus Therapeutics 10.16 Ariz Biopharma 10.17 Celsion Corporation 10.18 Ascletis Pharmaceuticals 11 RNAi for Therapeutic Manufacturing Cost Analysis 11.1 RNAi for Therapeutic Key Raw Materials Analysis 11.1.1 Key Raw Materials 11.1.2 Price Trend of Key Raw Materials 11.1.3 Key Suppliers of Raw Materials 11.1.4 Market Concentration Rate of Raw Materials 11.2 Proportion of Manufacturing Cost Structure 11.2.1 Raw Materials 11.2.2 Labor Cost 11.2.3 Manufacturing Expenses 11.3 Manufacturing Process Analysis of RNAi for Therapeutic 12 Industrial Chain, Sourcing Strategy and Downstream Buyers 12.1 RNAi for Therapeutic Industrial Chain Analysis 12.2 Upstream Raw Materials Sourcing 12.3 Raw Materials Sources of RNAi for Therapeutic Major Manufacturers in 2018 12.4 Downstream Buyers 13 Marketing Strategy Analysis, Distributors/Traders 13.1 Marketing Channel 13.1.1 Direct Marketing 13.1.2 Indirect Marketing 13.1.3 Marketing Channel Development Trend 13.2 Market Positioning 13.2.1 Pricing Strategy 13.2.2 Brand Strategy 13.2.3 Target Client 13.3 Distributors/Traders List 14 Market Effect Factors Analysis 14.1 Technology Progress/Risk 14.1.1 Substitutes Threat 14.1.2 Technology Progress in Related Industry 14.2 Consumer Needs/Customer Preference Change 14.3 Economic/Political Environmental Change 15 Asia-Pacific RNAi for Therapeutic Market Forecast ( 2019-2025) 15.1 Asia-Pacific RNAi for Therapeutic Sales Volume, Revenue and Price Forecast ( 2019-2025) 15.1.1 Asia-Pacific RNAi for Therapeutic Sales Volume and Growth Rate Forecast ( 2019-2025) 15.1.2 Asia-Pacific RNAi for Therapeutic Revenue and Growth Rate Forecast ( 2019-2025) 15.1.3 Asia-Pacific RNAi for Therapeutic Price and Trend Forecast ( 2019-2025) 15.2 Asia-Pacific RNAi for Therapeutic Sales Volume, Revenue and Growth Rate Forecast by Region ( 2019-2025) 15.2.1 Asia-Pacific RNAi for Therapeutic Sales Volume and Growth Rate Forecast by Region ( 2019-2025) 15.2.2 Asia-Pacific RNAi for Therapeutic Revenue and Growth Rate Forecast by Region ( 2019-2025) 15.2.3 China RNAi for Therapeutic Sales, Revenue and Growth Rate Forecast ( 2019-2025) 15.2.4 Japan RNAi for Therapeutic Sales, Revenue and Growth Rate Forecast ( 2019-2025) 15.2.5 South Korea RNAi for Therapeutic Sales, Revenue and Growth Rate Forecast ( 2019-2025) 15.2.6 Taiwan RNAi for Therapeutic Sales, Revenue and Growth Rate Forecast ( 2019-2025) 15.2.7 India RNAi for Therapeutic Sales, Revenue and Growth Rate Forecast ( 2019-2025) 15.2.8 Southeast Asia RNAi for Therapeutic Sales, Revenue and Growth Rate Forecast ( 2019-2025) 15.2.9 Australia RNAi for Therapeutic Sales, Revenue and Growth Rate Forecast ( 2019-2025) 15.3 Asia-Pacific RNAi for Therapeutic Sales, Revenue and Price Forecast by Type ( 2019-2025) 15.3.1 Asia-Pacific RNAi for Therapeutic Sales Forecast by Type ( 2019-2025) 15.3.2 Asia-Pacific RNAi for Therapeutic Revenue Forecast by Type ( 2019-2025) 15.3.3 Asia-Pacific RNAi for Therapeutic Price Forecast by Type ( 2019-2025) 15.4 Asia-Pacific RNAi for Therapeutic Sales Forecast by Application ( 2019-2025) 16 Research Findings and Conclusion 17 Appendix 17.1 Methodology/Research Approach 17.1.1 Research Programs/Design 17.1.2 Market Size Estimation 17.1.3 Market Breakdown and Data Triangulation 17.2 Data Source 17.2.1 Secondary Sources 17.2.2 Primary Sources 17.3 Disclaimer